C
Christoph Kettelhack
Researcher at University Hospital of Basel
Publications - 69
Citations - 2055
Christoph Kettelhack is an academic researcher from University Hospital of Basel. The author has contributed to research in topics: Sarcoma & Melanoma. The author has an hindex of 20, co-authored 66 publications receiving 1853 citations. Previous affiliations of Christoph Kettelhack include Max Delbrück Center for Molecular Medicine.
Papers
More filters
Journal ArticleDOI
Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.
Alexander M.M. Eggermont,Heimen Schraffordt Koops,Joseph M. Klausner,Bin B. R. Kroon,Peter M. Schlag,Danielle Liénard,Albertus N. van Geel,Harald J. Hoekstra,Isaac Meller,Omgo E. Nieweg,Christoph Kettelhack,Gur Ben-Ari,Jean Claude Pector,Ferdy Lejeune +13 more
TL;DR: The ILP with TNF + melphalan can be performed safely in many centers and is an effective induction treatment with a high response rate that can achieve limb salvage in patients with locally advanced extremity soft tissue sarcoma.
Journal ArticleDOI
High frequency of tumor‐infiltrating FOXP3+ regulatory T cells predicts improved survival in mismatch repair‐proficient colorectal cancer patients
Daniel M. Frey,Raoul A. Droeser,Carsten T. Viehl,Inti Zlobec,Alessandro Lugli,Urs Zingg,Daniel Oertli,Christoph Kettelhack,Luigi Terracciano,Luigi Tornillo +9 more
TL;DR: High frequency of tumor‐infiltrating FOXP3+ Treg is associated with early T stage and independently predicts improved disease‐specific survival in MMR‐proficient CRC patients.
Journal ArticleDOI
Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma.
Claus Garbe,Axel Hauschild,Matthias Volkenandt,Dirk Schadendorf,Wilhelm Stolz,Uwe Reinhold,Rolf-Dieter Kortmann,Christoph Kettelhack,Bernhard Frerich,Ulrich Keilholz,Reinhard Dummer,Günther Sebastian,Wolfgang Tilgen,Gerold Schuler,Andreas Mackensen,Roland Kaufmann +15 more
TL;DR: The most important prognostic factors for primary melanoma without metastases are vertical tumor thickness as measured on the histological specimen, presence of histopathologically recognized ulceration, invasion level and identification of micrometastases in the regional lymph nodes via sentinel lymph node biopsy.
Journal ArticleDOI
Short German guidelines : malignant melanoma
Claus Garbe,Dirk Schadendorf,Wilhelm Stolz,Matthias Volkenandt,Uwe Reinhold,Rolf-Dieter Kortmann,Christoph Kettelhack,Bernhard Frerich,Ulrich Keilholz,Reinhard Dummer,Günther Sebastian,Wolfgang Tilgen,Gerold Schuler,Andreas Mackensen,Roland Kaufmann,Axel Hauschild +15 more
TL;DR: The immunestatus of the patient plays a major role indetermining the course of melanoma, as numerous examples of spontaneous re-gression or of rapid progression in im-munosuppressed individuals bear testi-mony.
Journal ArticleDOI
Evidence and interdisciplinary consensus-based German guidelines: surgical treatment and radiotherapy of melanoma.
Claus Garbe,Axel Hauschild,Matthias Volkenandt,Dirk Schadendorf,Wilhelm Stolz,Uwe Reinhold,Rolf-Dieter Kortmann,Christoph Kettelhack,Bernhard Frerich,Ulrich Keilholz,Reinhard Dummer,Günther Sebastian,Wolfgang Tilgen,Gerold Schuler,Andreas Mackensen,Roland Kaufmann +15 more
TL;DR: The primary treatment of a melanoma is surgical excision, and an excisional biopsy is preferred, and safety margins of 1 cm for tumor thickness up to 2 mm and 2 cm for higher tumor thickness should be applied either at primary excision or in a two-step procedure.